Agility Robotics Goes Public in $2.5B SPAC Deal, Becoming First US-Listed Pure-Play Humanoid Maker•Google Delays Gemini 3.5 Pro to July 17 for Ground-Up Architectural Rebuild•ICML 2026 Wraps in Seoul: Record 24,000 Submissions, Agentic AI Everywhere, and a Peer-Review Reckoning•Twelve Deals in Eighteen Months: Why Ant Group Is Buying Into the Robot Future•From 'Best Model Wins' to 'Best Fit Wins': The Frontier AI Glut Is Rewriting the Race•Humanoid Robots Hit the Public Markets — and the Hype Meets Its First Earnings Test•Smart Glasses Maker Even Realities Hits $1B Valuation With $150M Round Led by Meituan and Tencent•Tripo AI Raises $150M Series A3 as 3D Foundation Models Push Toward Interactive Worlds•Agility Robotics Goes Public in $2.5B SPAC Deal, Becoming First US-Listed Pure-Play Humanoid Maker•Google Delays Gemini 3.5 Pro to July 17 for Ground-Up Architectural Rebuild•ICML 2026 Wraps in Seoul: Record 24,000 Submissions, Agentic AI Everywhere, and a Peer-Review Reckoning•Twelve Deals in Eighteen Months: Why Ant Group Is Buying Into the Robot Future•From 'Best Model Wins' to 'Best Fit Wins': The Frontier AI Glut Is Rewriting the Race•Humanoid Robots Hit the Public Markets — and the Hype Meets Its First Earnings Test•Smart Glasses Maker Even Realities Hits $1B Valuation With $150M Round Led by Meituan and Tencent•Tripo AI Raises $150M Series A3 as 3D Foundation Models Push Toward Interactive Worlds•Agility Robotics Goes Public in $2.5B SPAC Deal, Becoming First US-Listed Pure-Play Humanoid Maker•Google Delays Gemini 3.5 Pro to July 17 for Ground-Up Architectural Rebuild•ICML 2026 Wraps in Seoul: Record 24,000 Submissions, Agentic AI Everywhere, and a Peer-Review Reckoning•Twelve Deals in Eighteen Months: Why Ant Group Is Buying Into the Robot Future•From 'Best Model Wins' to 'Best Fit Wins': The Frontier AI Glut Is Rewriting the Race•Humanoid Robots Hit the Public Markets — and the Hype Meets Its First Earnings Test•Smart Glasses Maker Even Realities Hits $1B Valuation With $150M Round Led by Meituan and Tencent•Tripo AI Raises $150M Series A3 as 3D Foundation Models Push Toward Interactive Worlds•

Monday, July 13, 2026Independent AI & Tech Coverage — Asia Subscribe

AI & Technology Across Asia

BleepingComputer

Brief

Fable 5 Moves to Usage Credits July 8 — Anthropic Says the Change Is Temporary

Pro, Max and Team subscribers lose in-plan access to the flagship model this week as capacity constraints force metered billing at API rates.

M

Maya SantosSenior Reporter

July 6, 20262 min read

Anthropic's Claude Fable 5 comes off subscription plans this week. Through July 7, the flagship model remains included for Pro, Max, Team and select Enterprise users at up to 50 percent of weekly usage limits; from July 8, every Fable 5 token is billed through metered usage credits at standard API rates — $10 per million input tokens and $50 per million output.

The fine print: Enterprise Premium seats get the same July 7 grace period as consumer plans, while Standard seats do not. From July 8, consumer plan users must also verify their identity through Persona to retain access to the model.

Why it's happening: Capacity. Fable 5 returned to service on July 1 after a three-week export-control suspension, and demand since restoration has run well beyond what Anthropic can serve inside subscription economics.

Anthropic's position: The change is not permanent. A Claude Code lead engineer wrote that the company aims "to restore Fable as a standard part of our subscriptions as soon as capacity allows." No timeline was offered.

The context: The shift makes Fable 5 the first flagship model pulled from subscriptions into pure usage pricing — a live experiment in what frontier capability actually costs when unbundled. With GPT-5.6 Sol entering at $5/$30 in limited preview, the premium tier of the market is being repriced in real time, and subscribers are learning that "unlimited" plans were always a capacity bet.

Newsletter

Get Lanceum in your inbox

Weekly insights on AI and technology in Asia.

Share

More in Brief

Data visualization of the projected growth of the AI-in-pharmaceuticals market

AI-in-Pharma Market Projected to Hit $28.6 Billion by 2034 on Drug-Discovery Push

Chart from Healthcare Asia's report on AI in the pharmaceutical market

AI in Pharma Projected to Hit $28.6B by 2034 as Drug Discovery Push Accelerates

Timeline graphic of EU AI Act compliance milestones for 2026

EU Launches Cybersecurity-AI Action Plan as August Deadlines Close In